Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials ; volume:24 ; number:1 ; day:27 ; month:3 ; year:2024 ; pages:1-12 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (27.3.2024), 1-12, 12.2024
- Urheber
-
Peyrin‐Biroulet, Laurent
Arkkila, Perttu
Armuzzi, Alessandro
Danese, Silvio
Ferrante, Marc
Jordi Guardiola
Jahnsen, Jørgen
Louis, Edouard
Lukáš, Milan
Reinisch, Walter
Roblin, Xavier
Smith, Philip J.
Kwon, Taek
Kim, Jeeyoung
Yoon, Sangwook
Kim, Dong-Hyeon
Atreya, Raja
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-024-03163-5
- URN
-
urn:nbn:de:101:1-2406130857468.806109418787
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Peyrin‐Biroulet, Laurent
- Arkkila, Perttu
- Armuzzi, Alessandro
- Danese, Silvio
- Ferrante, Marc
- Jordi Guardiola
- Jahnsen, Jørgen
- Louis, Edouard
- Lukáš, Milan
- Reinisch, Walter
- Roblin, Xavier
- Smith, Philip J.
- Kwon, Taek
- Kim, Jeeyoung
- Yoon, Sangwook
- Kim, Dong-Hyeon
- Atreya, Raja
- SpringerLink (Online service)
Ähnliche Objekte (12)
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome
Effektivität und Sicherheit nach einem Switch vom Originator Infliximab auf das Biosimilar SB2 bei CED-Patienten: 24-Monatsdaten einer prospektiven Kohortenstudie
Targeting mucosal healing in Crohn’s disease: what the clinician needs to know
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Advanced Endoscopic Imaging for Diagnosis of Crohn's Disease
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Discrimination between Inflammatory and Fibrotic Activity in Crohn’s Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging
Update: chronisch entzündliche Darmerkrankungen
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Molekularer Wirkmechanismus eines TLR-9-Agonisten bei Colitis ulcerosa
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome
Effektivität und Sicherheit nach einem Switch vom Originator Infliximab auf das Biosimilar SB2 bei CED-Patienten: 24-Monatsdaten einer prospektiven Kohortenstudie
Targeting mucosal healing in Crohn’s disease: what the clinician needs to know
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Advanced Endoscopic Imaging for Diagnosis of Crohn's Disease
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Discrimination between Inflammatory and Fibrotic Activity in Crohn’s Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging
Update: chronisch entzündliche Darmerkrankungen
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases
Molekularer Wirkmechanismus eines TLR-9-Agonisten bei Colitis ulcerosa
Role of the IL23/IL17 Pathway in Crohn’s Disease
Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy
Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome
Effektivität und Sicherheit nach einem Switch vom Originator Infliximab auf das Biosimilar SB2 bei CED-Patienten: 24-Monatsdaten einer prospektiven Kohortenstudie
Targeting mucosal healing in Crohn’s disease: what the clinician needs to know
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Advanced Endoscopic Imaging for Diagnosis of Crohn's Disease
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Discrimination between Inflammatory and Fibrotic Activity in Crohn’s Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging
Update: chronisch entzündliche Darmerkrankungen
Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases